Page 7 - மருத்துவ புற்றுநோயியல் நிபுணர் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article SUZHOU, China, July 14, 2021 /PRNewswire/ Transcenta Holding Limited ( Transcenta ), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, announces that the first US patient has been dosed in the global Phase I clinical trial of PD-L1/TGF-β bi-functional antibody TST005. TST005 is the second bi-functional anti-PD-L1 and TGF-β trap fusion protein entering the global clinical stage. It simultaneously targets two immuno-suppressive pathways, transforming growth factor -β (TGF-β) and programmed cell death ligand-1 (PD-L1), that are commonly used by cancer cells to evade the immune system. TST005 consists of a high affinity PD-L1 antibody fused with an engineered TGF-β Receptor Type II protein in its C-terminal. TST005 lacks FcR binding activity and thus has reduced FcR mediated killing of PD-L1 expressing effector T cells. TST005 s high

United statesMichael shiAnthonyw tolcherPrnewswire transcenta holding limitedClinical development centersTranscenta holdingProduct development centerTranslational research centerBusiness developmentHolding limitedReceptor typeMedical oncologistManufacturing facilityExternal partnering centerஒன்றுபட்டது மாநிலங்களில்மைக்கேல் ஷி